In late August, the first 10 drugs subject to price negotiations under the Inflation Reduction Act (IRA) were announced. The White House and Medicare have both stated their intention to reduce drug costs for Medicare enrollees and taxpayers.

Experts from the USC Leonard D. Schaeffer Center for Health Policy & Economics, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and the the USC Sol Price School of Public Policy have offered their perspectives on what the negotiations could mean for the health care industry and patients alike.

To read their insights, click here.